EUVIMEDEUVIMED entdecken
Crossref

Multiomics analysis reveals serine catabolism as a potential therapeutic target for MELAS

Tongling Liufu iD, Xutong Zhao iD, Meng Yu iD, Zhiying Xie iD, Lingchao Meng, He Lv, Wei Zhang, Yun Yuan iD, Guogang Xing, Jianwen Deng iD, Zhaoxia Wang

The FASEB Journal · 2024

DOI: 10.1096/fj.202302286rrr ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, 2024. Verfasst von Tongling Liufu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: MELAS Syndrome, Glycine Hydroxymethyltransferase, Serine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: MOST | National Natural Science Foundation of China (NSFC), Beijing Nova Program, National High Level Hospital Clinical Research Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mitochondrial disease is a devastating genetic disorder, with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke‐like episodes (MELAS) and m.3243A>G being the most common phenotype and genotype, respectively. The treatment for MELAS patients is still less effective. Here, we performed transcriptomic and proteomic analysis in muscle tissue of MELAS patients, and discovered that the expression of molecules involved in serine catabolism were significantly upregulated, and serine hydroxymethyltransferase 2 (SHMT2) increased significantly in both the mRNA and protein levels. The SHMT2 protein level was also increased in myoblasts with m.3243A>G mutation, which was transdifferentiated from patients derived fibroblasts, accompanying with the decreased nicotinamide adenine dinucleotide (NAD + )/reduced NAD + (NADH) ratio and cell viability. After treating with SHMT2 inhibitor (SHIN1), the NAD + /NADH ratio and cell viability in MELAS myoblasts increased significantly. Taken together, our study indicates that enhanced serine catabolism plays an important role in the pathogenesis of MELAS and that SHIN1 can be a potential small molecule for the treatment of this disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MELAS SyndromeGlycine HydroxymethyltransferaseSerineHumansMyoblastsNADMaleProteomicsFemaleTranscriptomeMultiomics

Stichwörter der Autor:innen

M.3243 A>GMELASNADHSHIN1SHMT2multiomics

Substanzen

Glycine HydroxymethyltransferaseSerineSHMT protein, humanNAD

Autor:innen und Institutionen

  • Department of Neurology, Peking University First Hospital, Beijing, China.
  • Beijing Key Laboratory of Neurovascular Disease Discovery, Beijing, China.
  • Neuroscience Research Institute, Peking University, Beijing, China.
  • Key Laboratory for Neuroscience, Ministry of Education/National Health Commission, Peking University, Beijing, China.

ORCID-Profile: Tongling Liufu, Xutong Zhao, Meng Yu, Zhiying Xie, Yun Yuan, Jianwen Deng

Förderung

  • MOST | National Natural Science Foundation of China (NSFC)
  • Beijing Nova Program
  • National High Level Hospital Clinical Research Funding
  • National Natural Science Foundation of China

Zitieren

APA

Liufu, T., Zhao, X., Yu, M., Xie, Z., Meng, L., Lv, H., Zhang, W., Yuan, Y., Xing, G., Deng, J., & Wang, Z. (2024). Multiomics analysis reveals serine catabolism as a potential therapeutic target for MELAS. The FASEB Journal. https://doi.org/10.1096/fj.202302286rrr

Vancouver

Liufu T, Zhao X, Yu M, Xie Z, Meng L, Lv H, et al. Multiomics analysis reveals serine catabolism as a potential therapeutic target for MELAS. The FASEB Journal. 2024. doi:10.1096/fj.202302286rrr

BibTeX
@article{Liufu2024,
  author = {Liufu, Tongling and Zhao, Xutong and Yu, Meng and Xie, Zhiying and Meng, Lingchao and Lv, He and Zhang, Wei and Yuan, Yun and Xing, Guogang and Deng, Jianwen and Wang, Zhaoxia},
  title = {Multiomics analysis reveals serine catabolism as a potential therapeutic target for MELAS},
  journal = {The FASEB Journal},
  year = {2024},
  doi = {10.1096/fj.202302286rrr}
}
Kostenlos starten →